Multi-omics classification of acute myeloid leukemia guides drug combinations to overcome Venetoclax resistance
Cancer Drug Resistance · 26.03.2026
DOI: 10.20517/cdr.2025.228 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Drug Resistance, online erschienen am 26.03.2026. Verfasst von Runyu Yang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
Acute myeloid leukemia (AML) is an aggressive hematological malignancy. Conventional risk stratification in AML fails to predict patient responses to targeted therapies such as Venetoclax, hindering precision medicine and the development of strategies to overcome drug resistance.
Methods
We established an integrated multi-omics framework incorporating messenger RNA (mRNA)/long non-coding RNA (lncRNA) expression, DNA methylation, copy number alterations, and somatic mutation data. Using nine complementary clustering algorithms, we identified molecular subtypes in a discovery cohort and validated them in independent external cohorts. The multi-omics classification subsequently guided the screening of high-risk subtypes specific sensitizers to Venetoclax, with candidate efficacy validated through in vitro and in vivo experiments.
Results
We identified three molecularly distinct AML subtypes with unique clinical features, a classification that was subsequently validated in independent external cohorts. Cluster 2 demonstrated the most favorable prognosis, while Cluster 3, characterized by high tumor protein 53 (TP53) mutation frequency and significant immune infiltration, exhibited the poorest outcomes and pronounced resistance to Venetoclax. Multi-omics-guided drug screening revealed that Cluster 3 displays particular sensitivity to both Elesclomol and the clinically available proteasome inhibitor Bortezomib. Through comprehensive in vitro and in vivo validation, we demonstrated that both agents significantly enhance the therapeutic efficacy of Venetoclax. Of particular translational relevance, the Venetoclax-Bortezomib combination leverages an agent with an established safety profile, offering a readily implementable strategy for near-future clinical translation.
Conclusion
Our study establishes a novel multi-omics classification system that provides a robust foundation for investigating biological heterogeneity, elucidating resistance mechanisms, and developing effective combination strategies to achieve personalized therapy in AML.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi, China.
- These authors contributed equally to this work and share first authorship.
- Shaanxi University of Chinese Medicine, Xi'an-Xianyang New Economic Zone, Xi'an 712046, Shaanxi, China.
Zitieren
APA
Yang, R., Feng, H., Zhang, M., Liu, Y., Luo, M., Liu, R., Wang, K., Li, Q., Wang, W., Chen, J., Du, Y., Xiao, J., Yang, B., Niu, F., & He, P. (2026). Multi-omics classification of acute myeloid leukemia guides drug combinations to overcome Venetoclax resistance. Cancer Drug Resistance. https://doi.org/10.20517/cdr.2025.228
Vancouver
Yang R, Feng H, Zhang M, Liu Y, Luo M, Liu R, et al. Multi-omics classification of acute myeloid leukemia guides drug combinations to overcome Venetoclax resistance. Cancer Drug Resistance. 2026. doi:10.20517/cdr.2025.228
BibTeX
@article{Yang2026,
author = {Yang, Runyu and Feng, Hui and Zhang, Mengyao and Liu, Yi and Luo, Minna and Liu, Ruimin and Wang, Kaiyao and Li, Qijing and Wang, Wenjuan and Chen, Jing and Du, Yue and Xiao, Jiayi and Yang, Bingyu and Niu, Fan and He, Pengcheng},
title = {Multi-omics classification of acute myeloid leukemia guides drug combinations to overcome Venetoclax resistance},
journal = {Cancer Drug Resistance},
year = {2026},
doi = {10.20517/cdr.2025.228}
}
EUVIMED